#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Malignant glioma Mitochondrial myopathy Chorioretinitis Haemophilia Mantle cell lymphoma stage II Soft tissue sarcoma Nasopharyngeal cancer Urethral valves Pulmonary hypertension Leukoencephalopathy Renal cancer metastatic Blood iron increased Oropharyngeal cancer recurrent Paraneoplastic neurological syndrome Non-small cell lung cancer More trials…

    Learn about Rare Diseases

    Glomerulonephritis membranoproliferative – Trials in Disease Primary immunodeficiency syndrome – Life with Disease Burkitt’s lymphoma Adrenogenital syndrome – Basic Information Undifferentiated sarcoma – Trials in Disease Marginal zone lymphoma Hereditary optic atrophy – Treatment Mucopolysaccharidosis II – Treatment Small intestine leiomyosarcoma – Basic Information Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Argon Somatropin Morphine Hydrochloride Levocarnitine Belumosudil Mesilate Anidulafungin Elritercept Codeine Phosphate LUNSEKIMIG Oxygen Linaclotide ZIMISLECEL Serine Betula Pollen Extract Revumenib Procarbazine Hydrochloride Sodium Lactate Ucp4 Pegcetacoplan Frexalimab More therapies…

    Learn about Your Condition

    Urticaria cholinergic Antisynthetase syndrome Extra-osseous Ewing's sarcoma Primary myelofibrosis Metabolic disorder Epithelioid sarcoma Breast cancer recurrent Medullary thyroid cancer Intestinal ischaemia Ependymoma malignant Axial spondyloarthritis Polycystic liver disease IgA nephropathy Pigmentary glaucoma Primary hypercholesterolaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Myelofibrosis

  • A Study of Pacritinib for Reducing Bone Marrow Scarring in Patients with Myelofibrosis Who Have Low Platelet Counts

    Recruiting

    2 1 1
    Investigated Drugs:
    • Pacritinib
    Spain

  • Study of RVU120 treatment in patients with myelodysplastic syndrome, solid tumors, or acute myeloid leukemia who benefited from previous RVU120 therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Myelofibrosis
    • Myelodysplastic syndrome
    • Acute myeloid leukaemia
    Investigated Drugs:
    • 7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
    • Ruxolitinib
    • Venetoclax
    France Italy Poland Spain

  • Study on the Safety of Roginolisib and Ruxolitinib for Patients with Myelofibrosis Unresponsive to JAK Inhibitors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Myelofibrosis
    Investigated Drugs:
    • Fedratinib
    • Momelotinib Dihydrochloride Monohydrate
    • Roginolisib
    Italy Spain

  • Study of TP-3654 and Momelotinib for Patients with Intermediate or High-risk Myelofibrosis

    Recruiting

    1 1 1
    Investigated Diseases:
    • Myelofibrosis
    Investigated Drugs:
    • Momelotinib Dihydrochloride Monohydrate
    Austria Belgium Bulgaria Czechia Denmark France +7

  • Study on Long-Term Safety of Pelabresib for Patients with Myelofibrosis or Essential Thrombocythemia

    Recruiting

    3 1 1
    Investigated Diseases:
    • Myeloproliferative neoplasm
    • Myelofibrosis
    Investigated Drugs:
    • 2-((4S)-6-(4-Chlorophenyl)-1-Methyl-4H-Benzo[C]Isoxazolo[4,5-E]Azepin-4-Yl)Acetamide Monohydrate
    Belgium Italy The Netherlands

  • Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

    Recruiting

    3 1 1
    Investigated Drugs:
    • Loperamide Hydrochloride
    • Navtemadlin
    • Ruxolitinib
    Austria Belgium Croatia Czechia France Germany +7
1 2 3 … 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!